19
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      In vitro activity of gentamicin, vancomycin or amikacin combined with EDTA or l-arginine as lock therapy against a wide spectrum of biofilm-forming clinical strains isolated from catheter-related infections.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Treatment of catheter-related bloodstream infections (CRBSI) is hampered by the characteristic tolerance of bacterial biofilms towards antibiotics. Our objective was to study the effect of the combination of antibiotics and the alkaline amino acid l-arginine or the cation chelator EDTA on the bacterial killing of in vitro biofilms formed by an array of clinical strains responsible for CRBSI and representative of epidemiologically relevant bacterial species.

          Related collections

          Author and article information

          Journal
          J. Antimicrob. Chemother.
          The Journal of antimicrobial chemotherapy
          Oxford University Press (OUP)
          1460-2091
          0305-7453
          2015
          : 70
          : 6
          Affiliations
          [1 ] Institut Pasteur, Genetics of Biofilms Unit, Department of Microbiology, 28 rue du Dr Roux, 75724 Paris cedex 15, France Sorbonne Paris Cité, AP-HP, Hôpital Necker Enfants Malades, Centre d'Infectiologie Necker-Pasteur and Institut Imagine, Université Paris Descartes, 149 Rue de Sèvres, 75743 Paris cedex 15, France david.lebeaux@yahoo.fr.
          [2 ] Service de Microbiologie, Hôpital Beaujon, AP-HP, Clichy, France.
          [3 ] Institut Pasteur, Genetics of Biofilms Unit, Department of Microbiology, 28 rue du Dr Roux, 75724 Paris cedex 15, France.
          Article
          dkv044
          10.1093/jac/dkv044
          25712314
          f7312259-f998-47de-a9b2-74b1f266a6ca
          History

          persisters,adjuvant strategy,aminoglycosides,antibiotic lock therapy,in vitro models

          Comments

          Comment on this article